Related Experiment Video
Updated: Jun 27, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
[Rheology and coronary heart disease]
1Klinik für Kardiologie, Pneumologie und Angiologie, Klinikum Esslingen, Esslingen. m.leschke@klinikum-esslingen.de
Elevated fibrinogen levels increase blood viscosity, worsening coronary heart disease and angina. Fibrinogenolysis with urokinase improves blood flow and reduces symptoms in these patients.
Area of Science:
- Cardiovascular Medicine
- Hematology
Context:
- Hyperviscosity syndrome impacts blood flow parameters.
- Hyperfibrinogenemia and increased plasma viscosity are linked to coronary heart disease (CHD).
Purpose:
- To explore the role of fibrinogen in CHD and its impact on myocardial oxygen supply.
- To evaluate the efficacy of fibrinogenolysis for managing treatment-refractory angina.
Summary:
- Increased plasma viscosity due to high fibrinogen is a flow-limiting factor in poststenotic coronary microcirculation.
- Elevated fibrinogen levels correlate with cardiovascular event risk and are prominent in severe CHD with refractory angina.
- Chronic urokinase administration for fibrinogenolysis improved rheological parameters and significantly decreased angina symptoms.
Impact:
- Highlights the clinical significance of monitoring fibrinogen levels (>300 mg/dL) in atherosclerosis patients.
- Suggests fibrinogen-lowering therapy as a potential strategy for improving perfusion and symptom management in CHD.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Rheumatic Heart Disease III: Medical Management
